A High-throughput Approach to Identify Effective Systemic Agents for the Treatment of Anaplastic Thyroid Carcinoma.

Ying C HendersonAbdallah S R MohamedAnastasios ManiakasYunyun ChenReid T PowellShaohua PengMaria CardenasMichelle D WilliamsDiana BellMark E ZafereoRui Jennifer WangSteve E SchererDavid A WheelerMaria E CabanillasMarie-Claude HofmannFaye M JohnsonClifford C StephanVlad SandulacheStephen Y Lai

Published in: The Journal of clinical endocrinology and metabolism (2021)

HTS identified classes of systemic agents that demonstrate preferential effectiveness against aggressive thyroid cancers, particularly those with mutant TP53. Preclinical validation in both orthotopic and PDX models, which are accurate in vivo models mimicking tumor microenvironment, may support initiation of early-phase clinical trials in non-BRAF mutated or refractory to BRAF/MEK inhibition ATC.

Keyphrases

wild type
high throughput
clinical trial
randomized controlled trial
metastatic colorectal cancer
systematic review
high resolution
stem cells
single cell
cell therapy
young adults
mass spectrometry
drug induced
cell proliferation
phase ii
signaling pathway
phase iii